Objective: To evaluate the effect of time, temperature and storage vial material on the antiviral activity of 0.5% cidofovir solution.
Procedures: Commercial 7.5% cidofovir solution for injection was diluted with normal saline to a 0.5% concentration. Aliquots were stored in plastic and glass vials at 4, -20, and -80 degrees C for 30, 60, 120, and 180 days. Antiviral activity against feline herpesvirus was evaluated in a virus titration assay at time zero (baseline) and at each subsequent time point.
Results: Cidofovir caused a fourfold log reduction in virus titer at baseline and at each time point and for each storage condition (P < 0.001).
Conclusion: 0.5% cidofovir demonstrated stable antiviral activity when stored for up to 6 months in glass or plastic, at 4, -20, and -80 degrees C.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1463-5224.2010.00784.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy.
Transpl Infect Dis
December 2024
Department of Internal Medicine, University of Washington, Seattle, Washington, USA.
Background: BK polyomavirus-associated nephropathy (BKPyVAN) is an important cause of allograft dysfunction and failure in kidney transplant recipients (KTRs) and there are no proven effective treatments. Case reports and in vitro data support the potential activity of cidofovir against BK polyomavirus (BKPyV).
Methods: We report the results of a phase I/II, double-blind, placebo-controlled randomized dose-escalation trial of cidofovir in KTRs with biopsy-confirmed BKPyVAN and estimated glomerular filtration rate ≥30 mL/min.
Objective: To evaluate the long-term efficacy, prognostic factors, and complications of intravitreal cidofovir injection in dogs with end-stage glaucoma.
Animals: 130 client-owned dogs.
Methods: Medical records of dogs that underwent intravitreal cidofovir injections were reviewed.
[Expression of ProEXC and PRMT5 in cervical adenocarcinoma and their clinical significance].
Zhonghua Yi Xue Za Zhi
December 2023
Department of Gynecologic, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
This study observed the expression of ProEXC protein and PRMT5 protein in cervical adenocarcinoma and adjacent tissues, exploring the relationship between the expression of ProEXC and PRMT5 and the auxiliary diagnosis of cervical adenocarcinoma, as well as the clinical pathological parameters. A total of 88 specimens diagnosed with cervical adenocarcinoma from the Second Affiliated Hospital of Soochow University between 2015 and 2020 were collected. Immunohistochemistry was employed to detect the expression of ProEXC and PRMT5 in cervical adenocarcinoma and adjacent tissues, and statistical analysis was conducted.
View Article and Find Full Text PDFHuman herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
Clin Microbiol Infect
November 2023
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address:
Article Synopsis
- The study explores the effects of letermovir on the use of anti-CMV therapy and HHV-6 incidence in allogeneic HCT patients, indicating a significant reduction in broad-spectrum antiviral use post-letermovir.
- Analysis of 738 patients showed no significant change in the cumulative incidence of HHV-6 testing and detection between pre- and post-letermovir groups, with only minor differences in HHV-6-related conditions.
- Overall, despite the reduced use of broad-spectrum antivirals due to letermovir implementation, HHV-6 epidemiology remained stable, with no significant associations found related to HHV-6 detection rates.
Cyclopentenylcytosine (CPE-C): In Vitro and In Vivo Evaluation as an Antiviral against Adenoviral Ocular Infections.
Molecules
June 2023
The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Vision Institute, Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Adenoviruses are the major cause of ocular viral infections worldwide. Currently, there is no approved antiviral treatment for these eye infections. Cyclopentenylcytosine (CPE-C) is an antiviral that has demonstrated activity against more than 20 viruses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!